Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0387820120190020079
Clinical Pediatric Hematology-Oncology
2012 Volume.19 No. 2 p.79 ~ p.85
The Efficacy of Prophylaxis for Children with Severe Hemophilia in Korea - An Experience of Single Institute
Yoo Ki-Young

Choi Yong-Mook
Hwang Tae-Ju
Choi Eun-Jin
Abstract
Background: While primary prophylaxis is a well-established and recommended treat-ment for children with severe hemophilia, there has not been Korean own data. The aim of this study is to lay the foundation for the optimal and available management of hemophilia in Korea.

Methods: We reviewed the medical records of the patients treated with regular factor VIII concentrates infusion as long term continuous treatment at Seoul Clinic of Korea Hemophilia Foundation since August, 2004, retrospectively. We analyzed the efficacy of prophylaxis with the frequency of joint bleed and clinically meaningful bleeding episodes. We also assessed the cost of primary prophylaxis, secondary prophylaxis and on-demand therapy by the factor concentrates consumption.

Results: The data from 65 patients were available to evaluate. Of 65 patients, 22 were treated with primary prophylaxis, and 43 with secondary prophylaxis. In the primary and secondary prophylaxis groups, there were 1.9 joint bleeds and 3.3 other bleeding episodes, 7.2 and 9.0, respectively. The mean consumption of factor concentrates per person for primary prophylaxis, secondary prophylaxis and on-demand therapy groups were 2,658.8 IU/kg/year, 2,665.1 IU/kg/year, and 1,271.9 IU/kg/year respectively.

Conclusion: Now prophylaxis is the recommended treatment for severe hemophilia pa-tients, we should manage our hemophilia patients with standard treatment. And the opti-mizing treatment regimen for each individual will be needed to establish by studies of individual pharmacokinetics and bleeding tendency.
KEYWORD
Hemophilia, Prophylaxis, Primary prophylaxis
FullTexts / Linksout information
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø